RVL Pharmaceuticals (RVL Pharmaceuticals) GF Value : $1.11 (As of May. 31, 2024)

View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-31), RVL Pharmaceuticals's share price is $0.0005. RVL Pharmaceuticals's GF Value is $1.11. Therefore, RVL Pharmaceuticals's Price-to-GF-Value for today is 0.00.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes RVL Pharmaceuticals is Possible Value Trap, Think Twice.

RVL Pharmaceuticals (OTCPK:RVLPQ) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

RVL Pharmaceuticals's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0005	/	1.11
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals GF Value Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website

https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

Executives

Foundation Harsaul	10 percent owner	EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd	10 percent owner	KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p.	10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison	director, officer: Chief Executive Officer	501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman	director, 10 percent owner	C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell	10 percent owner	ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub	officer: EVP and COO	400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807